Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
He is currently president of the IEEE UFFC Society and is the co-founder and CTO of Acoustiic Inc, a medical therapy company.
Correia-Rodrigues A, Ribeiro-Rodrigues T, Goncalves L, Almeida JP, Ferreira MJ, Girao H
The interaction category that does apply here is pharmacodynamic overlap, meaning both substances influence the same biological pathways rather than altering each other's blood levels
Research applications In-vitro modeling of synergistic GHRH/GHRP receptor cross-talk Pre-clinical study of pulsatile GH-secretagogue dynamics Comparative receptor-pathway research (cAMP vs calcium convergence) Reference standard for analytical characterization of blended preparations Key facts Combines a GHRH-receptor analog with a selective GHS-R1a agonist Nominal 5mg + 5mg per-component loading per vial Components act through mechanistically independent, convergent pathways Supplied as a co-lyophilized research powder for in-vitro use Product specifications Class: GHRH analog + GHRP/ghrelin-receptor agonist research blend Also known as: Mod-GRF + Ipamorelin blend Form: Lyophilized powder vial Purity: 99% (HPLC verified) Testing: Independent third-party HPLC + mass spectrometry Documentation: Certificate of analysis per batch Storage: Store lyophilized at -20C
While GLP-1 medications help with weight loss and metabolic health, they can sometimes speed up muscle loss, skin thinning, and collagen decline
